S

Shukra Pharmaceuticals Ltd
BSE:524632

Watchlist Manager
Shukra Pharmaceuticals Ltd
BSE:524632
Watchlist
Price: 47.3 INR -4.98% Market Closed
Market Cap: 20.7B INR

Intrinsic Value

524632 doesn't have a meaningful market cap.

The intrinsic value of one SHUKRAPHAR stock under the Base Case scenario is 1.25 INR. Compared to the current market price of 47.3 INR, Shukra Pharmaceuticals Ltd is Overvalued by 97%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

SHUKRAPHAR Intrinsic Value
1.25 INR
Overvaluation 97%
Intrinsic Value
Price
S
Worst Case
Base Case
Best Case

Valuation History
Shukra Pharmaceuticals Ltd

What is Valuation History?
Ask AI Assistant
What other research platforms think about SHUKRAPHAR?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is SHUKRAPHAR valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Shukra Pharmaceuticals Ltd.

Explain Valuation
Compare SHUKRAPHAR to

Fundamental Analysis

Shukra Pharmaceuticals Ltd
Company Overview
Loading...
Economic Moat
Loading...
Contacts
Loading...
How do you feel about SHUKRAPHAR?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Shukra Pharmaceuticals Ltd

Current Assets 654.3m
Cash & Short-Term Investments 121.2m
Receivables 197.1m
Other Current Assets 336m
Non-Current Assets 213.4m
PP&E 213.4m
Current Liabilities 172.8m
Accounts Payable 92.2m
Other Current Liabilities 80.7m
Non-Current Liabilities 66.5m
Long-Term Debt 31.1m
Other Non-Current Liabilities 35.4m
Efficiency

Free Cash Flow Analysis
Shukra Pharmaceuticals Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Shukra Pharmaceuticals Ltd

Revenue
348m INR
Cost of Revenue
-88.7m INR
Gross Profit
259.4m INR
Operating Expenses
-158.2m INR
Operating Income
101.2m INR
Other Expenses
41k INR
Net Income
101.2m INR
Fundamental Scores

SHUKRAPHAR Profitability Score
Profitability Due Diligence

Shukra Pharmaceuticals Ltd's profitability score is 62/100. The higher the profitability score, the more profitable the company is.

Positive 3Y Average ROE
Positive 3Y Average ROIC
Exceptional Gross Margin
Healthy Operating Margin
62/100
Profitability
Score

Shukra Pharmaceuticals Ltd's profitability score is 62/100. The higher the profitability score, the more profitable the company is.

SHUKRAPHAR Solvency Score
Solvency Due Diligence

Shukra Pharmaceuticals Ltd's solvency score is 94/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
High Interest Coverage
Negative Net Debt
Low D/E
94/100
Solvency
Score

Shukra Pharmaceuticals Ltd's solvency score is 94/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

SHUKRAPHAR Price Targets Summary
Shukra Pharmaceuticals Ltd

There are no price targets for SHUKRAPHAR.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for SHUKRAPHAR is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y
What is the Intrinsic Value of one SHUKRAPHAR stock?

The intrinsic value of one SHUKRAPHAR stock under the Base Case scenario is 1.25 INR.

Is SHUKRAPHAR stock undervalued or overvalued?

Compared to the current market price of 47.3 INR, Shukra Pharmaceuticals Ltd is Overvalued by 97%.

Back to Top